Yonglong Han

1.2k total citations
48 papers, 948 citations indexed

About

Yonglong Han is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Yonglong Han has authored 48 papers receiving a total of 948 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 16 papers in Oncology and 13 papers in Pharmacology. Recurrent topics in Yonglong Han's work include Pharmacogenetics and Drug Metabolism (10 papers), Phytochemistry and Bioactive Compounds (6 papers) and Cancer Treatment and Pharmacology (6 papers). Yonglong Han is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Phytochemistry and Bioactive Compounds (6 papers) and Cancer Treatment and Pharmacology (6 papers). Yonglong Han collaborates with scholars based in China, South Korea and United States. Yonglong Han's co-authors include Cheng Guo, Quanjun Yang, Yan Huo, Lili Wan, Zhiyong Zhou, Qi Yu, Jinlu Huang, Genjin Yang, Jinmiao Lu and Hongliang Yu and has published in prestigious journals such as PLoS ONE, Molecules and Journal of Ethnopharmacology.

In The Last Decade

Yonglong Han

44 papers receiving 935 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yonglong Han China 21 411 194 188 155 123 48 948
Jianchang Qian China 23 719 1.7× 190 1.0× 222 1.2× 90 0.6× 137 1.1× 62 1.5k
Hatem A. Salem Egypt 22 443 1.1× 187 1.0× 268 1.4× 100 0.6× 151 1.2× 50 1.3k
Mohamed A. El‐Moselhy Egypt 19 294 0.7× 107 0.6× 116 0.6× 139 0.9× 92 0.7× 39 975
Yiwei Li China 17 457 1.1× 114 0.6× 71 0.4× 158 1.0× 86 0.7× 35 1.1k
Eman Said Egypt 23 562 1.4× 324 1.7× 199 1.1× 104 0.7× 188 1.5× 71 1.4k
Ying Yin China 19 496 1.2× 80 0.4× 85 0.5× 75 0.5× 144 1.2× 45 1.1k
Zeyao Tang China 21 681 1.7× 192 1.0× 88 0.5× 112 0.7× 73 0.6× 56 1.3k
Si Gao China 15 536 1.3× 112 0.6× 104 0.6× 80 0.5× 75 0.6× 23 1.1k
Nina Hanke Germany 20 299 0.7× 193 1.0× 308 1.6× 74 0.5× 119 1.0× 40 1.1k
Zhifu Yang China 21 504 1.2× 82 0.4× 120 0.6× 99 0.6× 158 1.3× 56 1.2k

Countries citing papers authored by Yonglong Han

Since Specialization
Citations

This map shows the geographic impact of Yonglong Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yonglong Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yonglong Han more than expected).

Fields of papers citing papers by Yonglong Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yonglong Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yonglong Han. The network helps show where Yonglong Han may publish in the future.

Co-authorship network of co-authors of Yonglong Han

This figure shows the co-authorship network connecting the top 25 collaborators of Yonglong Han. A scholar is included among the top collaborators of Yonglong Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yonglong Han. Yonglong Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiang, Danfeng, Xiangqi Zhang, Shuai Zhao, et al.. (2025). Marsdenia tenacissima extract accelerates ferroptosis of osteosarcoma cells by upregulating HO-1 and activating mitophagy. Journal of Ethnopharmacology. 350. 120055–120055. 1 indexed citations
2.
3.
Yang, Quanjun, Xiaohong Xu, Xia Wu, et al.. (2024). Outcome differences of starting Paxlovid for COVID-19 within or after five days of symptoms onset in the elderly: a retrospective study. The Journal of Infection in Developing Countries. 18(9). 1373–1379.
4.
Xu, Lingyan, et al.. (2024). P‐glycoprotein‐mediated herb–drug interaction evaluation between Tenacissoside G and paclitaxel. Biomedical Chromatography. 38(10). e5984–e5984. 1 indexed citations
5.
Yang, Quanjun, Xinting Zhu, Ping Huang, et al.. (2024). BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism. Molecular Therapy. 32(9). 3128–3144. 11 indexed citations
6.
Xiang, Danfeng, Quanjun Yang, Lingyan Xu, et al.. (2024). Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma. BMC Complementary Medicine and Therapies. 24(1). 67–67. 3 indexed citations
7.
Xu, Lingyan, et al.. (2024). Tongguanteng injection exerts anti-osteosarcoma effects through the ER stress-associated IRE1/CHOP pathway. BMC Complementary Medicine and Therapies. 24(1). 400–400. 3 indexed citations
8.
Yang, Jiao, Dan Li, Bo Jiang, et al.. (2022). Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo. Journal of Ethnopharmacology. 300. 115728–115728. 6 indexed citations
9.
Zhang, Xiangqi, Junjun Chen, Xiao Xiao, et al.. (2020). Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules. Journal of Ethnopharmacology. 261. 113067–113067. 21 indexed citations
10.
Chen, Min, et al.. (2020). Salvianolic acid B blocks hepatic stellate cell activation via FGF19/FGFR4 signaling. Annals of Hepatology. 20. 100259–100259. 22 indexed citations
11.
Chen, Junjun, Bo Jiang, Xiao Xiao, et al.. (2019). Effect of Xiao-Ai-Ping injection on paclitaxel pharmacokinetics in rats by LC–MS/MS method. Journal of Pharmaceutical and Biomedical Analysis. 174. 728–733. 21 indexed citations
12.
Yang, Quanjun, Genjin Yang, Yonglong Han, et al.. (2017). Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study. PLoS ONE. 12(1). e0169567–e0169567. 44 indexed citations
13.
Zhou, Zhiyong, Lili Wan, Quanjun Yang, et al.. (2016). Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model. Toxicology Letters. 259. 124–132. 31 indexed citations
14.
15.
Zhang, Xuehui, Hongliang Yu, Fujing Wang, Yonglong Han, & Wei-liang Yang. (2015). Pim-2 Modulates Aerobic Glycolysis and Energy Production during the Development of Colorectal Tumors. International Journal of Medical Sciences. 12(6). 487–493. 26 indexed citations
16.
Chen, Junming, et al.. (2014). Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases. European Journal of Cancer Prevention. 24(2). 89–99. 52 indexed citations
17.
Yang, Quanjun, Genjin Yang, Bin Li, et al.. (2013). Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice. Molecular BioSystems. 9(12). 3015–3025. 19 indexed citations
18.
Zhou, Zhiyong, Lili Wan, Quanjun Yang, et al.. (2013). Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib. Toxicology and Applied Pharmacology. 272(1). 238–244. 12 indexed citations
19.
Han, Yonglong, Hongliang Yu, Dan Li, et al.. (2011). Inhibitory effects of limonin on six human cytochrome P450 enzymes and P-glycoprotein in vitro. Toxicology in Vitro. 25(8). 1828–1833. 34 indexed citations
20.
Han, Yonglong, Dan Li, Zhiyong Zhou, et al.. (2011). Evaluation of impact of Herba Erigerontis injection, a Chinese herbal prescription, on rat hepatic cytochrome P450 enzymes by cocktail probe drugs. Journal of Ethnopharmacology. 139(1). 104–109. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianchang Qian Breakdown of academic impact, for papers by Hatem A. Salem Breakdown of academic impact, for papers by Mohamed A. El‐Moselhy Breakdown of academic impact, for papers by Yiwei Li Breakdown of academic impact, for papers by Eman Said Breakdown of academic impact, for papers by Ying Yin Breakdown of academic impact, for papers by Zeyao Tang Breakdown of academic impact, for papers by Si Gao Breakdown of academic impact, for papers by Nina Hanke Breakdown of academic impact, for papers by Zhifu Yang
Rankless by CCL
2026